Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02913261
Registration number
NCT02913261
Ethics application status
Date submitted
18/09/2016
Date registered
23/09/2016
Date last updated
8/02/2023
Titles & IDs
Public title
Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Query!
Scientific title
A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Query!
Secondary ID [1]
0
0
2016-002584-33
Query!
Secondary ID [2]
0
0
CINC424C2301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REACH2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Corticosteroid Refractory Acute Graft vs Host Disease
0
0
Query!
Condition category
Condition code
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ruxolitinib (RUX)
Treatment: Drugs - Best Available Therapy (BAT)
Experimental: Ruxolitinib - These patients were administered Ruxolitinib orally twice per day (b.i.d) at a dose of 10 mg bid, as two 5-mg tablets. Ruxolitinib was taken without regards to food.
Active Comparator: Best Available Therapy (BAT) - These patients were administered BAT per the Investigator's best judgement based on a specific list of BAT.
Treatment: Drugs: Ruxolitinib (RUX)
Ruxolitinib was provided as 5 mg tablets for oral use.
Treatment: Drugs: Best Available Therapy (BAT)
BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Response Rate (ORR) at Day 28
Query!
Assessment method [1]
0
0
Overall response rate at Day 28 after randomization was defined as the percentage participants in each arm demonstrating a complete response (CR) or partial response (PR), based on investigator assessment & according to standard criteria, without requirement for additional systemic therapies for an earlier progression, mixed response or non-response. Scoring of response was relative to the organ stage at the time of randomization.
CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs & symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.
PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Query!
Timepoint [1]
0
0
Day 28
Query!
Secondary outcome [1]
0
0
Durable Overall Response Rate (DORR) (Key Secondary Endpoint) at Day 56
Query!
Assessment method [1]
0
0
Percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56 based on investigator assessment and according to standard criteria.
CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.
PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Query!
Timepoint [1]
0
0
Day 56
Query!
Secondary outcome [2]
0
0
Overall Response Rate (ORR) at Day 14
Query!
Assessment method [2]
0
0
ORR at Da4 14 is the percentage of participants who achieved overall response (CR+PR) at Day 14 based on investigator assessment and according to standard criteria.
CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.
PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Query!
Timepoint [2]
0
0
Day 14
Query!
Secondary outcome [3]
0
0
Duration of Response (DOR)
Query!
Assessment method [3]
0
0
Duration of response was defined for patients who had a CR or PR at Day 28. This was the interval between the date of first documented response of CR or PR (i.e., the start date of response), till the date of progression or addition of systemic therapies for aGvHD on or after Day 28. Death without prior observation of aGvHD progression and onset of chronic GvHD were considered. Duration of response was censored at the last response assessment prior to or at the analysis cut-off date, if no events/competing risk occurred before or at the cut-off date.
Query!
Timepoint [3]
0
0
Up to 24 months
Query!
Secondary outcome [4]
0
0
Cumulative Steroid Dosing Until Day 56
Query!
Assessment method [4]
0
0
Weekly cumulative steroid dose for each participant up to Day 56 or discontinuation of randomized treatment. Participants should have undergone tapering of steroids if it had been required. Tapering the immunosuppression therapy was performed in 2 steps: Taper of corticosteroids: initiated not earlier than Day 7, and performed as per institutional guidelines. Only patients with assessments done at each time point are reported. This is the reason that the overall number per treatment is higher and the number of participants with responses vary over time.
Query!
Timepoint [4]
0
0
up to Day 56
Query!
Secondary outcome [5]
0
0
Kaplan Meier Estimates of Probability of Overall Survival (OS) by Time Interval
Query!
Assessment method [5]
0
0
OS was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.
Query!
Timepoint [5]
0
0
1, 2, 6, 12, 18 & 24 months
Query!
Secondary outcome [6]
0
0
Kaplan Meier Estimates of Probability of Event-free Survival (EFS) by Time Interval
Query!
Assessment method [6]
0
0
Event-free survival was defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. If a patient was not known to have any event, then EFS was censored at the latest date the patient was known to be alive (on or before the cut-off date). Results are based on Kaplan Meier (KM) estimates.
Query!
Timepoint [6]
0
0
1, 2, 6, 12, 18 & 24 months
Query!
Secondary outcome [7]
0
0
Cumulative Incidence Rate of Failure-Free Survival (FFS)
Query!
Assessment method [7]
0
0
FFS was defined as the time from the date of randomization to date of hematologic disease relapse/progression, non-relapse mortality, or addition of new systemic aGvHD treatment.
Probability of FFS with 95% CIs are presented for each treatment group, accounting for onset of chronic GvHD as the competing risk.
Query!
Timepoint [7]
0
0
1, 2, 6, 12, 18, & 24 Months
Query!
Secondary outcome [8]
0
0
Cumulative Probability of Non Relapse Mortality (NRM)
Query!
Assessment method [8]
0
0
NRM was defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression. Hematologic disease relapse/progression was considered a competing risk for NRM with the date of hematologic disease relapse/progression being the earlier of documented hematologic disease relapse/progression or institution of therapy to treat potential hematologic disease relapse/progression. If a patient was not known to have died or to have relapsed/progressed, then NRM was censored at the latest date the patient was known to be alive (on or before the cut-off date). Data is provided based on cumulative probability of hematologic disease relapse/progression.
Query!
Timepoint [8]
0
0
1, 2, 6, 12, 18 & 24 months
Query!
Secondary outcome [9]
0
0
Cumulative Probability of Malignancy Relapse/Progression (MR)
Query!
Assessment method [9]
0
0
MR was defined as the time from date of randomization to hematologic malignancy relapse/progression. Deaths not preceded by hematologic malignancy relapse/progression were considered competing risks. If a patient was not known to have event or competing risks, then MR was censored at the latest date the patient was known to be alive (on or before the cut-off date). Calculated for patients with underlying hematologic malignant disease.
Query!
Timepoint [9]
0
0
1, 2, 6, 12 , 18 & 24 months
Query!
Secondary outcome [10]
0
0
Cumulative Probability of Chronic Graft Versus Host Disease (cGvHD)
Query!
Assessment method [10]
0
0
Incidence of cGvHD was the time from date of randomization to onset of cGvHD is the diagnosis of any cGvHD including mild, moderate, severe. Deaths without prior onset of cGvHD and hematologic disease relapse/progression were competing risks. If a patient was not known to have event or competing risks, then the incidence of cGvHD was censored at the latest date the patient was known to be alive (on or before the cut-off date).
Query!
Timepoint [10]
0
0
1, 2, 6, 12, 18 & 24 months
Query!
Secondary outcome [11]
0
0
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Response Rate
Query!
Assessment method [11]
0
0
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect.
ORR was defined as the percentage of participants with a best overall response defined as complete response (CR) or partial response (PR) as assessed by local investigators. CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.
PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Query!
Timepoint [11]
0
0
Day 28
Query!
Secondary outcome [12]
0
0
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK- Durable Overall Response Rate (DORR)
Query!
Assessment method [12]
0
0
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect.
DORR is the percentage of all participants in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 (primary endpoint) AND maintained a CR or PR at Day 56.
CR was defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.
PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Query!
Timepoint [12]
0
0
Day 56
Query!
Secondary outcome [13]
0
0
Exposure-efficacy Relationship of Ruxolitinib in Corticosteroid Refractory aGvHD: PK-Overall Survival
Query!
Assessment method [13]
0
0
Exposure-efficacy relationship of ruxolitinib in terms of concentration-effect and dose-effect. This represents the percentage of Ruxolitinib-exposed participants dead at 24 months.
Overall survival (OS) was defined as the time from the date of randomization to date of death due to any cause. If a patient was not known to have died, then OS was censored at the latest date the patient was known to be alive (on or before the cut-off date).the date of death due to any cause.
Query!
Timepoint [13]
0
0
up to 24 months
Query!
Secondary outcome [14]
0
0
Best Overall Response Rate (BOR)
Query!
Assessment method [14]
0
0
Percentage of participants who achieved overall response (OR) (CR+PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD.
CR was defined as a score of 0 for the Acute Graft vs. Host Disease (aGvHD) grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.
PR was defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.
Query!
Timepoint [14]
0
0
up to Day 28
Query!
Secondary outcome [15]
0
0
Patient Reported Outcomes (PROs): Change From Baseline in Functional Assessment of Cancer Therapy-Bone Marrow Transplantation (FACT-BMT) Total Score
Query!
Assessment method [15]
0
0
The Functional assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family and emotional well-being, together with additional concerns relevant for bone marrow transplantation patients. Patients indicated their response on a scale of 0 to 4 on each statement, with 0 indicating worst score and 4 the best score. All individual scores were combined to calculate the total score. Total score was reported with score range: 0-148 which was calculated as the sum of all unweighted subscale scores. The higher the total score the better the result. Descriptive statistics and change from baseline were calculated in total score at each scheduled assessment time point.
Query!
Timepoint [15]
0
0
Baseline, Week 24
Query!
Secondary outcome [16]
0
0
Patient Reported Outcomes (PROs): Change From Baseline in EuroQol-5D-5L UK Score
Query!
Assessment method [16]
0
0
The EQ-5D descriptive classification consists of five dimensions of health: mobility, self-care, usual activities, anxiety/depression and pain/discomfort. Patients are requested to select the statement which best describes their condition on that day for each dimension. For overall health that day, the EuroQoL-5D-5L scale is numbered from 0 to 100, with 100 being the best health you can imagine and 0 being the worst health you can imagine. Descriptive statistics (mean, standard deviation, median, Q1, Q3, minimum, and maximum) were calculated based on the scored scales at each scheduled assessment time point. In order to measure Quality-of-Life (QoL) among aGvHD patients, and potential changes over time, change from baseline in EuroQol-5D-5L scores at the time of each assessment were also calculated. Missing items data in a scale will be handled based on each instrument manual. No imputation will be applied if the total or subscale scores are missing at a visit.
Query!
Timepoint [16]
0
0
Baseline, Week 24
Query!
Secondary outcome [17]
0
0
Pharmacokinetic (PK) Parameter: Area Under the Curve (AUC) (AUCinf, AUClast, AUCtau) of Ruxolitinib
Query!
Assessment method [17]
0
0
AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1) AUCinf: The AUC from time zero to infinity (mass x time x volume-1) AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1).
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [17]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [18]
0
0
Pharmacokinetic (PK) Parameter: Plasma Concentration at Peak (Cmax) of Ruxolitinib
Query!
Assessment method [18]
0
0
Cmax is the maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass X volume-1).
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients was assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [18]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [19]
0
0
Pharmacokinetic (PK) Parameter: CL/F of Ruxolitinib
Query!
Assessment method [19]
0
0
CL/F is the total body clearance of ruxolitinib from the plasma after a single dose and at steady state.
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients was assayed for Ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [19]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [20]
0
0
Pharmacokinetic (PK) Parameter: VzF of Ruxolitinib
Query!
Assessment method [20]
0
0
VzF is the apparent volume of distribution during terminal phase after a single dose and at steady state.
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [20]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [21]
0
0
Pharmacokinetic (PK) Parameter: Lambda_z of Ruxolitinib
Query!
Assessment method [21]
0
0
Lambda_z is the smallest (slowest) disposition (hybrid) rate constant (hr-1) may also be used for terminal elimination rate constant (hr-1).
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [21]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [22]
0
0
Pharmacokinetic (PK) Parameter: T1/2 of Ruxolitinib
Query!
Assessment method [22]
0
0
T1/2 is the elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve (hr).
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [22]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [23]
0
0
Pharmacokinetic (PK) Parameter: Tmax of Ruxolitinib
Query!
Assessment method [23]
0
0
Tmax is the time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose and repeated dose administration (hr).
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [23]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [24]
0
0
Pharmacokinetic (PK) Parameter: Racc of Ruxolitinib
Query!
Assessment method [24]
0
0
Racc is the accumulation ratio (AUC at steady state/AUC Day 1). Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients was be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS).
Query!
Timepoint [24]
0
0
pre-dose, 0.5, 1, 1.5, 2, 4, 6, 9 hrs post-dose
Query!
Secondary outcome [25]
0
0
Pharmacokinetic (PK) Parameter: Ctrough of Ruxolitinib
Query!
Assessment method [25]
0
0
Minimum concentration (Ctrough) of ruxolitinib and at steady state in corticosteroid refractory acute GVHD patients.
Plasma samples for PK was taken at Day 1 (start of treatment), at Day 7 (week 1) to characterize the PK after first dose, and at steady state by non-compartmental analysis.
The plasma samples from all patients will be assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method (LC-MS/MS)
Query!
Timepoint [25]
0
0
pre-dose
Query!
Eligibility
Key inclusion criteria
- Have undergone Allogeneic Stem Cell Transplanttaion (alloSCT) from any donor source
(matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral
blood stem cells, or cord blood. Recipients of non- myeloablative, myeloablative, and
reduced intensity conditioning are eligible
- Clinically diagnosed Grades II to IV acute GvHD as per standard criteria occurring
after alloSCT requiring systemic immune suppressive therapy. Biopsy of involved organs
with aGvHD is encouraged but not required for study screening.
- Confirmed diagnosis of steroid refractory aGvHD defined as patients administered
high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent
prednisone dose 2.5 mg/kg/day]), given alone or combined with calcineurin inhibitors
(CNI) and either:
- Progressing based on organ assessment after at least 3 days compared to organ
stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for
the treatment of Grade II-IV aGvHD, OR
- Failure to achieve at a minimum partial response based on organ assessment after
7 days compared to organ stage at the time of initiation of high-dose systemic
corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD,OR
- Patients who fail corticosteroid taper defined as fulfilling either one of the
following criteria:
- Requirement for an increase in the corticosteroid dose to methylprednisolone =2
mg/kg/day (or equivalent prednisone dose =2.5 mg/kg/day) , OR
- Failure to taper the methylprednisolone dose to <0.5 mg/kg/day (or equivalent
prednisone dose <0.6 mg/kg/day) for a minimum 7 days.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Has received more than one systemic treatment for steroid refractory aGvHD.
- Presence of an active uncontrolled infection including significant bacterial, fungal,
viral or parasitic infection requiring treatment. Infections are considered controlled
if appropriate therapy has been instituted and, at the time of screening, no signs of
progression are present. Progression of infection is defined as hemodynamic
instability attributable to sepsis, new symptoms, worsening physical signs or
radiographic findings attributable to infection. Persisting fever without other signs
or symptoms will not be interpreted as progressing infection.
- Evidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr
Virus (EBV), Human Herpes Virus-6 (HHV-6), Hepatitis Virus (HBV), or Hepatitis C Virus
(HCV) based on assessment by the treating physician.
- Presence of relapsed primary malignancy, or who have been treated for relapse after
the alloHSCT was performed, or who may require rapid immune suppression withdrawal as
pre-emergent treatment of early malignancy relapse.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
10/03/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/04/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
310
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Westmead
Query!
Recruitment hospital [2]
0
0
Novartis Investigative Site - Herston
Query!
Recruitment hospital [3]
0
0
Novartis Investigative Site - Parkville
Query!
Recruitment hospital [4]
0
0
Novartis Investigative Site - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [3]
0
0
3002 - Parkville
Query!
Recruitment postcode(s) [4]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
Austria
Query!
State/province [1]
0
0
Graz
Query!
Country [2]
0
0
Austria
Query!
State/province [2]
0
0
Linz
Query!
Country [3]
0
0
Bulgaria
Query!
State/province [3]
0
0
Sofia
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Alberta
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
British Columbia
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Ontario
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Quebec
Query!
Country [8]
0
0
Canada
Query!
State/province [8]
0
0
Saskatchewan
Query!
Country [9]
0
0
Czechia
Query!
State/province [9]
0
0
Czech Republic
Query!
Country [10]
0
0
Denmark
Query!
State/province [10]
0
0
Copenhagen
Query!
Country [11]
0
0
France
Query!
State/province [11]
0
0
Loire
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Angers Cedex 1
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Besancon cedex
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Grenoble
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Lille
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Limoges cedex
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Nice Cedex
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Paris Cedex 10
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Paris Cedex
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Paris
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Pessac
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Pierre Benite Cedex
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Toulouse
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Vandoeuvre les Nancy cedex
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Baden-Wuerttemberg
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Augsburg
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Berlin
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Dresden
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Duesseldorf
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Essen
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Freiburg
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Hamburg
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Hannover
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Jena
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Leipzig
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Mainz
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Muenster
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Tübingen
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Ulm
Query!
Country [40]
0
0
Greece
Query!
State/province [40]
0
0
GR
Query!
Country [41]
0
0
Hong Kong
Query!
State/province [41]
0
0
Hong Kong
Query!
Country [42]
0
0
Israel
Query!
State/province [42]
0
0
Haifa
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Jerusalem
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Petach Tikva
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Tel Aviv
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
AN
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
BG
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
BO
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
BS
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
FG
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
FI
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
GE
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
MI
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
RM
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
TO
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
UD
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Aichi
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Fukuoka
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Hokkaido
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Hyogo
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Kanagawa
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Miyagi
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Okayama
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Osaka
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Tokyo
Query!
Country [66]
0
0
Korea, Republic of
Query!
State/province [66]
0
0
Seoul
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
The Netherlands
Query!
Country [68]
0
0
Norway
Query!
State/province [68]
0
0
Oslo
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Moscow
Query!
Country [70]
0
0
Saudi Arabia
Query!
State/province [70]
0
0
Riyadh
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Andalucia
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Asturias
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Catalunya
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Pontevedra
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Madrid
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Malaga
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Valencia
Query!
Country [78]
0
0
Taiwan
Query!
State/province [78]
0
0
Taichung
Query!
Country [79]
0
0
Turkey
Query!
State/province [79]
0
0
Ankara
Query!
Country [80]
0
0
Turkey
Query!
State/province [80]
0
0
Istanbul
Query!
Country [81]
0
0
Turkey
Query!
State/province [81]
0
0
Izmir
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
London
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Assess the efficacy and safety of ruxolitinib compared to Best Available Therapy (BAT) in
patients with corticosteroid-refractory acute graft vs. host disease (aGvHD) after allogeneic
stem cell transplantation.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02913261
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02913261
Download to PDF